Abstract
PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.
Original language | English |
---|---|
Pages (from-to) | 4083-4092 |
Number of pages | 10 |
Journal | Anticancer Research |
Volume | 29 |
Issue number | 10 |
Publication status | Published - Oct 2009 |
Externally published | Yes |
Keywords
- Adjuvant therapy
- Capecitabine
- Hepatocellular carcinoma (HCC)
- PHY906
- Phase I/II
ASJC Scopus subject areas
- Oncology
- Cancer Research